Skip to Main Content

Last year, researchers at the University of Pennsylvania, led by immunotherapy pioneer Carl June, showed that it was safe and feasible to treat cancer patients with infusions of their own immune cells that had been edited with the technology known as CRISPR.

The trial was small, and the patients weren’t cured of their cancer. The study was designed only to test safety.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment